• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Chermaine Lee

Articles by Chermaine Lee

China's Bio-Thera launches phase III trial of HER2-positive breast cancer ADC candidate

Nov. 9, 2018
By Chermaine Lee
HONG KONG – Chinese biologics and biosimilars maker Bio-Thera Solutions Ltd. kicked off a phase III trial of its HER2 antibody-drug conjugate (ADC), BAT-8001, targeting HER2-positive metastatic cancer.
Read More

Lucence's breast cancer test seeks to avoid removing healthy tissue

Nov. 8, 2018
By Chermaine Lee

Philips launches two Ingenia MRI machines in Singapore

Nov. 7, 2018
By Chermaine Lee

Japan's Kissei to commercialize Rigel's Tavalisse in East Asia

Nov. 7, 2018
By Chermaine Lee
HONG KONG – Rigel Pharmaceuticals Inc. has joined forces with Japan's Kissei Pharmaceutical Co. Ltd. to develop and commercialize Rigel's small molecule inhibitor, Tavalisse (fostamatinib), in Japan, the Chinese mainland, Taiwan and South Korea for all potential indications.
Read More

Japan’s Kissei to commercialize Rigel’s Tavalisse in East Asia

Nov. 7, 2018
By Chermaine Lee
HONG KONG – Rigel Pharmaceuticals Inc. has joined forces with Japan’s Kissei Pharmaceutical Co. Ltd. to develop and commercialize Rigel’s small molecule inhibitor, Tavalisse (fostamatinib), in Japan, the Chinese mainland, Taiwan and South Korea for all potential indications.
Read More

Singapore steps up efforts to develop cancer immunotherapy imaging

Oct. 31, 2018
By Chermaine Lee

Conba establishes Shanghai subsidiary while Genor plans potential Hong Kong IPO

Oct. 30, 2018
By Chermaine Lee

HONG KONG – China's Zhejiang Conba Pharmaceutical Co. Ltd. is working on a ¥960 million (US$138.3 million) plan to focus on foreign investment and take biosimilar maker Genor Biopharma Co. Ltd. public in Hong Kong.


Read More

Samsung Medison unveils new HERA W10 ultrasound system in Singapore

Oct. 25, 2018
By Chermaine Lee

Conba establishes Shanghai subsidiary while Genor plans potential Hong Kong IPO

Oct. 25, 2018
By Chermaine Lee
HONG KONG – China's Zhejiang Conba Pharmaceutical Co. Ltd. is working on a ¥960 million (US$138.3 million) plan to focus on foreign investment and take biosimilar maker Genor Biopharma Co. Ltd. public in Hong Kong.
Read More

Zejula gets Hong Kong nod for second-line ovarian cancer maintenance

Oct. 24, 2018
By Chermaine Lee
HONG KONG – China biopharmaceutical firm Zai Lab Ltd. bagged marketing approval from Hong Kong's Department of Health this week for its PARP inhibitor, Zejula (niraparib), targeting patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian cancer. It is intended for second-line maintenance use for adult ovarian cancer patients.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe